Vilket är priset för Heidelberg Pharma AG (HPHA)

Priset för Heidelberg Pharma AG (HPHA) är $2.99

Vilket är marknadsvärdet för Heidelberg Pharma AG (HPHA)

Marknadsvärdet för Heidelberg Pharma AG (HPHA) är $139.84M

Heidelberg Pharma AG (HPHA) Utestående Aktier

Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.

År	Utestående aktier	Ändra
Inte tillräckligt med data för de angivna datumen.

År

Utestående aktier

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	Utestående aktier	Skillnad	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
Moderna, Inc. MRNA.US	396.00M	-	US
CSL Limited CSL.AX	478.91M	-	AU
Lonza Group AG LONN.SW	-	-	CH

Företag

Utestående aktier

Skillnad

Land